Key facts
- This page summarizes Vifor (International) Ltd's Form 4 filing for ChemoCentryx, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Oct 2021, 19:05.
Vifor (International) Ltd - 12 Oct 2021 Form 4 Insider Report for ChemoCentryx, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 12 Oct 2021
- Net transaction value
- -$157,720,000
- SEC form
- 4
- Accepted by SEC
- 13 Oct 2021, 19:05:19 UTC
- Next SEC filing
- 21 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- VIFOR (INTERNATIONAL) LTD, By: /s/ Markus Frenzen, Title: Group Treasurer, /s/ Georg Frey, Title: Head Legal Corporate
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vifor (International) Ltd filed Form 4 for ChemoCentryx, Inc. on 13 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$157,720,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CCXI
transaction
Common Stock, par value $0.001 per share
Sale
- Transaction value
- $157,720,000
- Shares
- -4,000,000
- Change %
- -44%
- Price
- $39.43
- Shares after
- 5,194,085
- Date
- 12 Oct 2021
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Vifor (International) Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities").
Footnote F2
Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 1,860,752 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP.
Footnote F3
Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.